[Previous (#11)] [Contents] [Psychedelics] [Home]

DMT Bibliography

Some of these articles are available on the web (there are a few active links below, where known). Strassman [111c] and [111d] also have many references to scientific studies.

[0] Johnny Appleseed: "Ayahuasca Analog Plant Complexes of the Temperate Zone: Phalaris arundinacea and the Desmanthus spec.", integration, no. 4 (1993), pp. 59-62.

[1] Arnold, O. H., and Hofmann, G.: "Zur Psychopathologie des Dimethyltryptamin: ein weiterer Beitrag Zur Pharmakopsychiatrie", Wien. Zeitschr. Nervenh., 13 (1957), pp. 438-445.

[2] Axelrod, J.: "Enzymatic formation of psychotomimetic metabolites from normally occurring compounds", Science,134 (1961), p.343.

[3] Axelrod, J.: "The enzymatic N-methylation of serotonin and other amines", J. Clin. Endocrinol. Metab., 61 (1962), pp. 388-390.

[4] Barker, S. A., Monti, J. A., and Christian S. T.: "N,N-Dimethyltryptamine: an Endogenous Hallucinogen", International Review of Neurobiology, 22 (1981), pp. 83-110.

[4a] Baxter, C. and Slaytor, M.: "Biosynthesis and turnover of N,N-dimethyltryptamine and 5-methoxy-N,N-dimethlytryptamine in Phalaris tuberosa", Phytochemistry, 11, pp. 2767-2773.

[5] Beaton, J. and Morris, P.: "Ontogeny of N,N-dimethyltryptamine and related indolealkylamine levels in neonatal rats", Mech. Age. Develop., 25, pp. 343-347.

[6] Benington, F., Morin, R. D., and Clark, L. C.: "5-Methoxy-N,N-dimethyltryptamine, a possible endogenous psychotoxin", Journal of Medical Sciences, 2 (1965), pp. 397-403.

[7] Bickel, P., Dittrich, A., and Schoepf, J: "Eine experimentelle Untersuchung zur bewusstseinverandenden Wirkung von N,N-Dimethyl-tryptamine (DMT)", Pharmakopsychiatr. Neuropsychopharmakol., 9 (1976), pp. 220-225.

[7a] Bigwood, J. and Ott, J.: "DMT", Head.

[8] Borsey, J., Lénárd, K. and Csizmadia, Zs.: "Über die zentrale Wirkung von Diäthyltryptamin und seiner an 2. Stelle substituierten aromatischen Derivative im Zusammenhang mit den Mediatorsubstanzen der autonomen Zentren", Acta Physiol. Acad. Sci. Hung., 18 (1961), pp. 83-84.

[9] Boszormenyi, Z., Der, P. and Nagy, T.: "Observations on the psychotogenic effect of N,N-diethyltryptamine, a new tryptamine derivative", J. Ment. Sci., 105 (1959), 171-181.

[9a] Boszormenyi, Z. and Brunecker, G.: "Dimethyltryptamine (DMT) experiments with psychotics", in [30], pp. 580-581.

[9b] ---- and Szá, S.: "Dimethyltryptamine experiments with psychotics", J. of Mental Sciences, 104, pp. 445-453.

[10] Bradley, P. B., Deniker, P., and Radouco-Thomas, C. (eds): Neuropsychopharmacology, Elsevier, 1959.

[11] ----, Flügel, F. and Hoch, P. H. (eds.): Neuropharmacology, Vol. III, Proceedings of the Third Meeting of the Collegium Internationale Neuro-Psychopharmacologicum, Elsevier, 1964.

[12] Brimblecombe and Pinder: Hallucinogenic Agents.

[13] Brune, G. B. and Pscheidt, G. R.: "Correlations between behavior and urinary excretion of indole amines and catecholamines in schizophrenic patients as affected by drugs", Federation Proc., 20, No. 4 (December 1961), pp. 889-893.

[14] Burroughs, W. S., and Ginsberg, A.: The Yagé Letters, City Lights Books, 1988.

[14a] Callaway, J. C., Airaksinen, M. M., and Gynther, J.: "Endogenous ß-carbolines and Other Indole Alkaloids in Mammals", integration, no. 5 (1994), pp. 19-33.

[15] Castaneda, C.: The Teachings of Don Juan: A Yaqui Way of Knowledge, Touchstone, 1968.

[16] Cerletti, A., Taeschler, M., and Weidmann, H.: "Pharmacologic studies on the structure-activity relationship of hydroxyindole alkylamines", Adv. Pharmacol. Chemother., 6B (1968), pp. 233-246.

[17] Christian, S. T., et al.: "The in Vitro Identification of Dimethyltryptamine (DMT) in Mammalian Brain and its Characterization as a Possible Endogenous Neuroregulatory Agent", Biochemical Medicine, 18 (1977), pp. 164-183.

[18] Corbett, L. et al.: British Journal of Psychiatry 132 (1978), pp. 139-144.

[19] Cottrell, A., McLeod, M. and McLeod, W.: "A bufotenin-like substance in the urine of schizophrenics", Am. J. Psychiatry, 134, pp. 322-323.

[20] DeMontigny, C. and Aghajanian, G.: "Preferential action of 5-methoxy-tryptamine and 5-methoxy-dimethyl-tryptamine on presynaptic serotonin receptors: A comparative iontophoretic study with LSD and serotonin", Neuropharmacology, 77 (1977), pp. 811-818.

[21] Evans-Wentz, W. Y.: The Fairy Faith in Celtic Countries (introduction by T. McKenna), Citadel Press, 1990.

[22] Fabing, H. D.: "On going berserk: a neurochemical inquiry", Am. J. Psychiat., 113 (1956), pp. 409-415.

[23] ---- and Hawkins, J. R.: "Intravenous bufotenine injection in the human being", Science, 123 (1956), pp. 885-887.

[24] ---- et al.: "Bufotenine effects in humans", Fed. Proc., 15 (1956), p.421.

[25] Fish, M.S., Johnson, N. M. and Horning, E. C.: J. Am. Chem. Soc., 77 (1955), p.5892.

[26] ---- and Horning, E.C.: "Studies on Hallucinogenic Snuffs", J. Nerv. & Ment. Dis., 124 (1956), pp. 33-37.

[27] Fisher, G.: "Some Comments concerning Dosage Levels of Psychedelic compounds for Psychotherapeutic Experiences", Psychedelic Review, 2 (Fall 1963), pp. 208-218.

[28] Flammarion, C.: Mysterious Psychic Forces, Boston, 1907.

[29] Freedman, D. X.: "Aspects of the Biochemical Pharmacology of Psychotropic Drugs", Psychedelic Review, 8 (1966), pp. 33-58. Reprinted from Solomon [105].

[30] Garattini, S. and Ghetti, V. (eds): Psychotropic Drugs, Elsevier, 1957.

[30a] Gartz, J.: "Eine neuere Methode der Pilzzucht aus Nordamerika" ["A new method of musthroom cultivation from North America], integration, no. 4 (1993), pp. 37-38.

[30b] Gartz, J.: Narrenschwämme, Editions Heuwinkel.

[31] Geppinger, H. C.: DMT: Dimensional Motion Times, Development and Application (1897, reprinted Wiley, 1955)

[32] Gessner, P.K, McIsaac, W. M. and Page, I. H.: "Pharmacological actions of some methoxyindole-alkylamines", Nature, 190 (1961), pp. 179-180.

[33] ---- et al.: "The relation between the metabolic fate and pharmacological actions of serotonin, bufotenine and psilocybin", J. Pharmacol. Exp. Therap., 130 (1960), pp. 126-133.

[34] ---- and Page, I. H.: "Behavioral effects of 5-methoxy-N,N-dimethyltryptamine, other tryptamines, and LSD", Am. J. Physiol., 203 (1962), pp. 167-172.

[35] ---- and Dankova, J: "Brain bufotenine from administered acetylbufotenine: Comparison of its tremorigenic activity with that of N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine", Pharmacologist, 17 (1975), p.259.

[36] Giarman, N. J.: Discussion of Kety [61], Federation Proc., Vol. 20, No. 4 (December 1961), pp. 897 - 900.

[37] Gillin, J. et al.: "The psychedelic model of schizophrenia: The case of N,N-dimethyl-tryptamine", Am. J. Psychiatry, 133 (1976), pp. 203-208.

[38] ----, Stoff, D. M., and Wyatt, R. J.: "Transmethylation hypothesis: A review of progress", in [64], pp. 1097-1112.

[39] ---- et al.: "5-Methoxy-N,N-dimethyltryptamine: Behavioral and toxicological effects in animals", Biol. Psychiatry, 11 (1976), pp. 355-358.

[40] Glennon, R. A., Liebowitz, S. M. and Mack, E. C.: "Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues", J. med. Chem., 21 (1978), pp. 822-825.

[41] ---- et al.: "Bufotenine esters", J. med. Chem., 22 (1979), pp. 1414-1416.

[42] ----, Young, R., and Jacyno, J. A: "Indolealkylamine and phenylalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substitutents on behavioural activity.", Biochem. Pharmac., 32 (1983), pp. 1267-1273.

[43] ----, Titeler, M. and McKenney, J: "Evidence for 5HT2 involvement in the mechanism of action of hallucinogenic agents", Life Sci., 35 (1984), pp. 2505-2511.

[44] Gracie & Zarkov, Notes from Underground, privately printed, 1985.

[45] Granier-Doyeux, M.: "Una Toxicomania Indígena: El Uso de la Piptadenia peregrina", Revista Técnica, 2 (1956), pp. 49-55.

[46] Gucchait, R.: "Biogenesis of 5-methoxy-N,N-dimethyl-tryptamine in human pineal gland", J. Neurochem., 26 (1976), pp. 187-190.

[47] Guenter, G. B., and Pscheidt, G. R.: "Correlations between behavior and urinary excretion of indole amines and catecholamines in schizophrenic patients as affected by drugs", Feder. Proc., 20 (1961), pp. 889-893.

[48] Harner, M. (ed.): Hallucinogens and Shamanism, Oxford University Press, 1973.

[49] Hartley, R. and Smith, J.: "The activation of pineal hydroxy-indole-O-methyltransferase by psychotomimetic drugs", J. Pharm. Pharmacol., 25 (1973), pp. 751-752.

[50] Heinze, W. et al.: "The acute and chronic affect of 5-methoxy-tryptamine on selected members of a primate social colony", Biol. Psychiatry, 15 (1980), pp. 829-838.

[51] Hess, S. M., Redfield, B. G, and Udenfriend, S.: "The effect of monoamine oxidase inhibitors and typtophan on the tryptamine content of animal tissues and urine," J. Pharmacol. Exp. Ther., Vol. 127 (1959), pp. 178-181.

[52] Himwich, H. E., Kety, S. S. and Smythies, J. R. (eds): Amines and Schizophrenia, Pergamon Press, 1967.

[53] ----: "Introductory Remarks" to symposium, "Effects of Hallucinogenic Drugs in Man", Federation Proc., Vol. 20, No. 4 (December 1961), pp. 874-875.

[54] Hofmann, A. et al.: Experientia, vol. 14 (1958), p. 107.

[55] Holmstedt, B.: "Tryptamine derivatives in Epena, in intoxicating snuff used by some South American Indians", Arch. Int. Pharmacodyn. Ther., 156 (1965), pp. 285-305.

[56] Horowitz, M. and C.: Shaman Woman / Mainline Lady: Women's Writings on the Drug Experience.

[56a] Huxley, A.: The Doors of Perception, 1954.

[57] Jacobs, B. L. (ed.): Hallucinogens: Neurochemical, Behavioral and Clinical Perspectives, Raven Press, New York, 1984.

[58] Janiger, Oscar: verbal communication, February 1991.

[59] Karkkainen, J.et al.: "Urinary excretion of free bufotenin by psychiatric patients", Biol. Psychiatry, 24 (1988), pp. 441-446.

[60] Kensinger, K. M.: "Banisteriopsis Usage Among the Peruvian Cashinahua", in [48], pp. 9-14.

[61] Kety, S. S. : "Possible relation of central amines to behavior in schizophrenic patients", Federation Proc., Vol. 20, No. 4 (December 1961), pp. 894 - 896.

[62] Kusel, H.: "Ayahuasca Drinkers among the Chama Indians of North-East Peru", Psychedelic Review, 6 (1965), pp. 58-66.

[63] Leary, T.: "Programmed Communication during Experiences with DMT (Dimethyltryptamine)", Psychedelic Review, 8 (1966), pp. 83-95.

[63a] Lin, G. C. and Glennon, R. A. (eds.): Hallucinogens: An Update, NIDA Research Monograph 146, 1994.

[64] Lipton, M. A., DiMascio, A. and Killam, K. F. (eds): Psychopharmacology: A Generation of Progress, Raven Press, 1978.

[64a] Luna, L. E.: "Plant Spirits in Ayahuasca Visions by Peruvian Painter, Pablo Amaringo. An Iconographic Analysis", integration, no. 1 (1991), pp. 18-29.

[64b] Lyttle, T.: "Psychedelica mysticae: White Light Drugs and the Search for the Pineal", integration, no. 4 (1993), pp. 29-36.

[65] Mandel, L. and Walker, R.: "The biosynthesis of 5-methoxy-N,N-dimethyl-tryptamine in vitro", Life Sci., 15 (1971), pp. 1457-1463.

[66] McKenna, D.: "Biochemistry and pharmacology of tryptamines and beta-carbolines: A minireview", J. Psychoactive Drugs, 16 (1984), pp. 347-357.

[66a] ----: "Bitter brews and other abominations: The uses and abuses of some little-known hallucinogenic plants", integration, no. 5 (1995), pp. 99-104.

[67] ---- et al.: "Differential Interactions of Indolealkylamines with 5-Hydroxytryptamine Receptor Subtypes", Neuropharmacology, 29 (1990), pp. 193-198.

[68] ---- and McKenna, T.: The Invisible Landscape, Seabury Press, 1975.

[69] McKenna, T.: "Among Ayahuasquera", in [84], pp. 179-211.

[70] ----: Wahre Halluzinationen (Gaia Media AG, 1991)

[71] ----: True Hallucinations (audio cassette tapes).

[72] ----: "Tryptamine Hallucinogens and Consciousness", Jahrbuch für Ethonomedizin und Bewußtseinsforschung (Yearbook for Ethnomedicine and the Study of Consciousness), Vol. I (1992), ed. Dr. Chr. Rätsch, pp. 133-147. Originally an audio cassette tape, Esalen, December 1982, Dolphin Tapes.

[73] ----: Psilocybin and the Sands of Time (audio cassette tape, Esalen, 1982-12, Dolphin Tapes)

[73a] ----: Understanding and Imagination in the Light of Nature (audio cassette tape, Los Angeles, 1987-10, Dolphin Tapes)

[73a] ----: Food of the Gods, 1992, Bantam.

[74] ---- and Abraham, R.: Dynamics of Hyperspace (audio cassette tape, Santa Cruz, June 1983, Dolphin Tapes).

[75] McLeod, W. R., and Sitaram, B. R.: "Bufotenine reconsidered", Acta psychiatr. scan., 72 (1985), pp. 447-450.

[76] Metzner, R.: "The Pharmacology of Psychedelic Drugs", Psychedelic Review, 1 (Summer 1963), pp. 69-115.

[77] ----: "Hallucinogens in Contemporary North American Shamanic Practice", Proceedings of the Fourth International Conference on the Study of Shamanism and Alternate Modes of Healing (1987), p. 171 - 175.

[78] Misztal, S.: "Synteza N,N-dwumetylo-5-hydroksytryptaminy I N-Metylo-5-metoksytryptaminy", Diss. Pharmaceut., 11 (1959), pp. 11-15.

[79] Murphree, H. B. et al.: "Effects in Normal Man of alpha-methyltryptamine and alpha-ethyl-tryptamine", Clin. Pharmacol. Therapeut, 2 (1961), pp. 722-726.

[80] Naranjo, C.: "Psychotherapeutic possibilities of new fantasy-enhancing drugs," Clin. Toxicol., 2 (1969), pp. 209-224.

[81] Nichols, David E. and Glennon, Richard A.: "Medicinal Chemistry and Structure-Activity Relationships of Hallucinogens", in [57], pp. 95-142.

[82] ----: "Studies of the relationship between molecular structure and hallucinogenic activity", Pharmac. Biochem. Behav., 24 (1986), pp. 335-340.

[82a] Ott, J.: Pharmacotheon, Natural Products Co., 1993. (Sales: J. Ott, P.O. Box 1251, Occidental, CA 95465, USA) The Proemium of this book is available on the web (this site is mirrored).

[82b] ----: Ayahuasca Analogues. (Tables of information from this book.)

[82c] ----: "Ayahuasca - ethnobotany, phytochemistry and human pharmacology", integration, no. 5 (1995), pp. 73-97.

[83] Pfeifer, A. K., Sátory, E., Pataky, I. and Vizy, E.: "Einfluß der Tranquillantien auf die Wirkung von Diäthyltryptamin (DET)", Acta Physiol. Acad. Sci. Hung., 18 (1961), pp. 82-83.

[83a] Pletscher, A. and Ladewig, D. (eds.): 50 Years of LSD: Current Status and Perspectives of Hallucinogens, Parthenon, 1994.

[84] Rätsch, C. (ed.): "Gateway to Inner Space", Prism Press, 1989.

[85] Repke, D. B., Grotjahn, D. B., and Shulgin, A. T.: "Psychotomimetic N-methyl-N-isopropyl-tryptamines. Effects of variation of aromatic oxygen substituents", J. med. Chem., 28, pp. 892-896.

[86] Richards, W.A. et al.: "The peak experience variable in DPT-assisted psychotherapy with cancer patients.", J. Psychedelic Drugs, 9 (1977), pp. 1-10.

[87] Richter, D. (ed.): Comparative Neurochemistry, Pergamon Press, 1964.

[88] Rivier, L. and Lindgren, J.-E.: "Ayahuasca, the South American hallucinogenic drink: an ethnobotanical and chemical investigation", Econ. Bot., 26 (1972). pp. 101-129.

[89] Rosenberg, D. E., Isbell, H. and Miner, E.J.: "Comparison of a placebo, N-dimethyltryptamine and 6-hydroxy-N-dimethyltryptamine in man", Psychopharmacologia, 4 (1963), pp. 39-42.

[90] Saavedra, J. and Axelrod, J.: "Psychotomimetic N-methylated tryptamines: Formation in brain in vivo and in vitro", Science, 24 (1872), pp. 1365-1366.

[91] Sai-Halasz, A., Brunecker, G. and Szara, S.: Psych. Neurol., 135 (1958), p.285.

[92] ---- and Endroczy, E.: "The Effect of Tryptamine Derivatives on the Behaviour of Dogs During Brain-Stem Stimulation", in [10] or [11], pp. 405-407.

[93] Sátory, E., Pfeifer, A. K., Pataky, I. and Kerekes, L.: "Die Wirkung von Diäthyltryptamin auf die Monoaminoxydase-Aktivität", Acta Physiol. Acad. Sci. Hung., 18 (1961), p. 83.

[94] Schlemmer, R. F. et al.: "The effect of a hallucinogen, 5-methoxy-N,N-dimethyltryptamine, on primate social behavior", Commun. Psychopharmacol., 1(1977), pp. 105-118.

[95] Schultes, R. E.: "Botanical Sources of the New World Narcotics", Psychedelic Review, 2 (Fall 1963), pp. 145-166. Reprinted in [129].

[96] ----: Where the Gods Reign, Synergetic Press, 1988.

[97] ---- and Hofmann , A.: Plants of the Gods: Origins of Hallucinogenic Use, McGraw-Hill, 1979.

[98] ---- and ----: The Botany and Chemistry of Hallucinogens, revised and enlarged second edition, Thomas, 1988.

[98a] Shulgin, A. T.: "Stereospecific requirements for hallucinogenesis", J. of Pharmaceutical Pharmacology, 1973.

[98b] ----: "Profiles of Psychedelic Drugs: DMT", J. of Psychedelic Drugs, 8, pp. 167-168.

[99] ---- and Carter, M. F.: "N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity.", Psychopharmacol. Commun., 1 (1975), pp. 93-98.

[100] Siegel, R. K., and Jarvik. M.E.: "DMT self-administration by monkeys in isolation", Bull. Psychonomic Soc., 16 (1980), pp. 117-120.

[101] ----: Intoxication, Simon & Schuster, 1989.

[102] Smith, M. V.: Psychedelic Chemistry

[103] Smythies, J. R, Bradley, R. J., and Johnston, V.S.: "The behavioral effects of some derivatives of mescaline and N,N-dimethyltryptamine in the rat.", Life Sci, 6 (1967), pp. 1887-1893.

[104] ----, Morin, R. D. and Brown, G. D.: "Identification of dimethyltryptamine and O-methylbufotenine in human cerebrospinal fluid by combined gas chromatography/mass spectrometry", Biol. Psychiat., 14 (1979), pp. 549-556.

[105] Solomon, P. (ed.): Psychiatric Drugs, Grune & Stratton, 1966.

[106] Soskin, R. A.: "Dipropyltryptamine in psychotherapy", Curr. Psychiatr. Ther., 15 (1975), pp. 147-156.

[107] ----, Grof, S., and Richards, W. A.: "Low doses of dipropyltryptamine in psychotherapy.", Arch. Gen. Psychiatry, 28 (1973), pp. 817-822.

[108] Stafford, P.: Psychedelics Encyclopedia, 3rd edition, Ronin Publishing, 1991.

[109] Stillman, R. C., and Willette, R. E. (eds): The Psychopharmacology of Hallucinogens, Pergamon, 1978.

[110] Strassman, R. J.: "The Pineal Gland: Current Evidence for its Role in Consciousness", Psychedelic Monographs and Essays, Volume 5 (1991), pp. 167-205.

[111] ----: "Human Hallucinogenic Drug Research: Regulatory, Clinical, and Scientific Issues", in [63a], pp. 92-123.

[111a] ----: "Human psychopharmacology of LSD, dimethyltryptamine and related compounds", in [83a], pp. 145-174.

[111b] ----: "Hallucinogenic Drugs in Psychiatric Research and Treatment: Perspectives and Prospects", The Journal of Nervous and Mental Disease, Vol. 183, No. 3 pp. 127-138. [111c] ---- and Qualls, C. R.: "Dose-Response Study of N,N-Dimethyltryptamine in Humans, Part I: Neuroendocrine, Autonomic, and Cardiovascular Effects", Arch. Gen. Psychiatry, Volume 51, Feb. 1994, pp. 85-97.

[111d] ----, ----, Uhlenhuth, E. H. and Kellner, R.: "Dose-Response Study of N,N-Dimethyltryptamine in Humans, Part II: Subjective Effects and Preliminary Results of a New Rating Scale", Arch. Gen. Psychiatry, Volume 51, Feb. 1994, pp. 98-108.

[112] Szara, S.: Experientia, 12 (1956), p.441.

[113] ----: "The comparison of the psychotic effect of tryptamine derivatives with the effects of mescaline and LSD-25 in self experiments", in [30], pp. 460-467.

[114] ----: "Hallucinogenic effects and metabolism of tryptamine derivatives in man", Federation Proc., 20 (1961), pp. 885-888.

[115] ----: "Correlation between metabolism and behavioral action of psychotropic tryptamine derivatives", Biochem. Pharmacol., 8 (1961), p. 32.

[116] ----: "Effect of psychotropic tryptamine derivatives on the regional distribution of serotonin in the brain", in [10].

[117] ----: "Behavioral correlates of 6-hydroxylation and the effect of psychotropic tryptamine derivatives on brain serotonin levels", in [87], pp. 432-452.

[118] ---- and Axelrod, J.: "Hydroxylation and N-demethylation of N,N-dimethyltryptamine", Experientia, 15 (1959), pp. 216-219.

[119] ----, ---- and Hearst, E.: "The 6-hydroxylation of tryptamine derivatives: a way of producing psychoactive metabolites", Ann. N. Y. Acad. Sci., 96 (1962), pp. 134-141.

[120] ----, ---- and ----: "Metabolism of Hallucinogenic Tryptamine Derivatives" (intr. by J. Axelrod), Clinical Neuropharmacology Research Center, NIMH. Abstract in Federation Proc., 19 (1960), p. 23

[121] ----, ---- and ----: "Metabolism and behavioral action of psychotropic tryptamine homologues", Int. J. Neuropharmacol., 1 (1962), pp. 111-117

[122] ----, Hearst, E. and Putney, F.: "Metabolism and behavioral action of psychotropic tryptamine homologues", Int. J. Neuropharmacol., 1 (1962), pp. 111-117.

[123] ---- et al.: "Psychological effects and metabolism of N,N-diethyltryptamine in man", Arch. Gen. Psychiatry, 15 (1966), pp. 320-329.

[124] Taborsky, R. G., Delvigs, P., and Page, I. H.: "6-Hydroxylation: Effect on the psychotropic potency of tryptamines", Science, 153 (1966), pp. 1018-1020.

[125] Tanimukai, H. et al.: "Detection of psychotomimetic N,N-dimethylated indoleamines in the urine of four schizophrenic patients", Brit. J. Psychiat., 117 (1970), pp. 421-430.

[125a] Torres, C. M.: "Snuff trails of Atacama: Psychedelics and iconography in prehispanic San Pedro de Atacama", integration, no. 4 (1993), pp. 17-28.

[125a] Turner, D. M.: The Essential Psychedelic Guide, Panther Press, 1994.

[126] Turner, W. J. and Merlis, S.: "Effect of Some Indolealkylamines on Man", A. M. A. Archives of Neurology and Psychiatry, 81 (January 1959), p.121.

[127] Uyeno, E. T.: "6-Hydroxylated N,N-dimethyltryptamines and hallucinogenic potency", Proc. West. Pharmacol. Soc., 12 (1969), pp. 118-123.

[128] Weidmann, H., and Cerletti, A.: "Studies on psilocybin and related compounds", Helv. Physiol. Acta, 18 (1960), pp. 174-182.

[129] Weil, G. M., Metzner, R. and Leary, T. (eds.): The Psychedelic Reader (selected articles from Psychedelic Review), University Books,1965.

[130] Wieland, T., and Motsel, W.: "Über das Vorkommen von bufotenin im gelben Knollenblätterpilz", Liebig. Ann. Chem., 581 (1953), pp. 10-16.

[131] Wyatt, R., Saavedra, J. and Axelrod, J.: "A dimethyltryptamine-forming enzyme in human blood", Am. J. Psychiatry, 130 (1973), pp. 754-760.

[Top of page] [Previous (#11)] [Contents] [Psychedelics] [Home]